JPMorgan lowered the firm’s price target on AnaptysBio (ANAB) to $66 from $75 and keeps an Overweight rating on the shares. The firm updated models in the Smid-cap biotechnology space.
Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
The Fly
AnaptysBio price target lowered to $66 from $75 at JPMorgan
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App